Clinical trials: Respiratory Disorders
Hypoxic Ischemic Encephalopathy
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
The goal is to see whether topiramate (an anti-epileptic agent) improves the outcome of babies with neonatal hypoxic encephalopathy who are receiving whole body cooling.
- Trial name
- NCT01765218
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Kristin R Hoffman
Asthma
Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances.
- Trial name
- NCT00200850
- Testing
- House Dust Mite SLIT, High dose SLIT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a maintenance treatment of Pemetrexed and Bevacizumab.
- Trial name
- NCT01004250
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Where
- 19 sites in Denmark, Germany and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Acute Respiratory Distress Syndrome
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- START (NCT01775774)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Michael A. Matthay
Respiratory Tract Infection, Respiratory Syncytial Virus
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational…
- Trial name
- NCT03524118
- Testing
- Clesrovimab
- Where
- 34 sites in United States, Chile and 4 more
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cardiac Arrest
Reoxygenation After Cardiac Arrest II (REOX II Study)
The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome.
- Trial name
- REOX II (NCT02698826)
- Testing
- Protocol for rapid FiO2 optimization
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- The Cooper Health System
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan.
- Trial name
- REFALS-ES (NCT03948178)
- Testing
- Levosimendan
- Where
- 79 sites in United States, Australia and 12 more
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Constrictive Bronchiolitis, Bronchiolitis Obliterans
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Background: Bronchiolitis obliterans or bronchiolitis obliterans syndrome is a lung disorder that occurs as a complication of either lung transplantation or bone marrow/blood stem cell transplantation.
- Conditions
- Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative
- Trial name
- NCT01287078
- Testing
- Cyclosporine Inhalation Solution
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA.
- Trial name
- Quercetin (NCT01708278)
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan
Asthma
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)
This is a randomized, multicenter, double blind, parallel-group study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) compared with MF MDI 400 mcg…
- Trial name
- NCT00381485
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI)
- Volunteers
- 834 people
- Sponsor
- Organon and Co
Asthma, Obesity
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
This project will assess the effectiveness of omega-3 fatty acid supplementation in controlling asthma symptoms among obese asthmatics, and will assess if a person's genes influence response to treatment (personalized medicine).
- Trial name
- NOOA (NCT01027143)
- Testing
- omega-3 polyunsaturated fatty acids, Omega-3 Fatty Acid
- Where
- 3 sites in United States
- Volunteers
- 143 people
- Sponsor
- Nemours Children's Clinic
COVID-19
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious…
- Trial name
- BIRCH (NCT05603143)
- Testing
- Obeldesivir
- Where
- 81 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 468 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets…
- Trial name
- NCT03187678
- Testing
- i.v. selexipag, oral selexipag (Uptravi)
- Where
- 8 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Actelion
Lung Cancer, Non-Small Cell
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer.
- Trial name
- PEARL (NCT01853878)
- Testing
- Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
- Where
- 39 sites in United States, Estonia and 7 more
- Volunteers
- 137 people
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Tract Infections
Patient Portal - Flu Reminder Recall
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive…
- Conditions
- Influenza, Respiratory Tract Infections, Vaccines
- Trial name
- NCT03666026
- Testing
- 1 MyChart R/R, 2 MyChart R/R, 3 MyChart R/R
- Where
- United States
- Volunteers
- 164,205 people
- Sponsor
- University of California, Los Angeles
Asthma
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.
- Trial name
- NCT01609478
- Testing
- indacaterol, mometasone furoate
- Where
- 96 sites in Bulgaria, Canada and 6 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Graft-Versus-Host Disease
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
To test a new agent, LBH589, in combination with glucocorticoids as initial therapy of acute graft versus host disease (GVHD).
- Trial name
- NCT01111526
- Testing
- Panobinostat (LBH589)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small…
- Trial name
- ASTRIS (NCT02474355)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 201 sites in Argentina, Australia and 14 more
- Volunteers
- 3,017 people
- Sponsor
- AstraZeneca
Asthma
The Effect of NAC on Lung Function and CT Mucus Score
This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging.
- Trial name
- ENACT (NCT03822637)
- Testing
- n-acetylcystine + albuterol, 0.9% saline + albuterol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.